Net cash (used in) provided by
financing activities (3,000) 261,000
Net increase in cash and cash equivalents 1,974,000 910,000
Cash and cash equivalents at beginning of period 4,384,000 5,730,000
Cash and cash equivalents at end of period $6,358,000 $6,640,000
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress(TM) and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.
-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from plasma
in about an hour. The CryoSeal FS System is approved in the U.S. for liver
resection surgeries. The CryoSeal FS System has received the CE-Mark which
allows sales of the product throughout the European community. Asahi
Medical is the exclusive distributor for the
'/>"/>
| SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved |